Stem Cells Treatment for Subarachnoid Hemorrhage

Area of Science:

• Neuroscience
• Regenerative Medicine
• Cell Therapy

Background:

• Subarachnoid hemorrhage (SAH) is a severe neurological emergency with limited treatment options.
• Stem cell (SC) therapy is emerging as a promising research area for SAH treatment.

Purpose of the Study:

• To review the current state of stem cell therapy for subarachnoid hemorrhage.
• To summarize the types of stem cells used, their mechanisms of action, administration methods, and timing.
• To assess the potential and limitations of SC therapy in SAH treatment.

Main Methods:

• Review of existing studies on stem cell therapy for SAH.
• Analysis of stem cell types, dosages, administration routes, and timing.
• Evaluation of reported mechanisms, including differentiation, migration, anti-apoptosis, anti-inflammation, and BBB protection.

Main Results:

• Commonly used SCs include bone marrow mesenchymal stem cells (BMSCs), umbilical cord mesenchymal stem cells (hUC-MSCs), dental pulp stem cells (DPSCs), neural stem cells (NSCs)/neural progenitor cells (NPCs), and endothelial progenitor cells (EPCs).
• Mechanisms involve tissue repair, reduced neuronal apoptosis, anti-inflammatory effects, and blood-brain barrier protection.
• SC dosages are typically around 10^6, with administration via intravenous, nasal, or intraventricular routes, generally within hours to days post-SAH.

Conclusions:

• Stem cell therapy holds significant potential for treating SAH, supported by preliminary case reports.
• Current research is insufficient, with a lack of extensive clinical trials to validate SC therapy's effectiveness and safety for SAH.